Premium
Favorable outcome with direct‐acting antiviral treatment in hepatitis C patients coinfected with HIV
Author(s) -
Ishida Hisashi,
Ishihara Akio,
Tanaka Satoshi,
Iwasaki Tetsuya,
Hasegawa Hiroko,
Akasaka Tomofumi,
Sakakibara Yuko,
Nakazuru Shoichi,
Uehira Tomoko,
Shirasaka Takuma,
Mita Eiji
Publication year - 2019
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.13360
Subject(s) - sofosbuvir , ledipasvir , medicine , ribavirin , adverse effect , genotype , hepatitis c virus , hepatitis c , coinfection , gastroenterology , human immunodeficiency virus (hiv) , virology , virus , biochemistry , chemistry , gene
Aim To investigate the efficacy and safety of all‐oral direct‐acting antiviral treatments in patients coinfected with hepatitis C virus (HCV) and HIV. Methods In all, 35 patients with HCV/HIV coinfection (22 patients with HCV genotype 1 infection, 6 with genotype 2, and 7 with genotype 3) were treated with sofosbuvir and ledipasvir (for genotype 1 patients) or sofosbuvir and ribavirin (for genotypes 2 and 3). Sustained virological response (SVR) at 24 weeks after end of treatment and adverse events were assessed. Results The overall SVR rate was 91.4% (32/35). One patient with genotype 1 infection discontinued treatment on day 2 due to severe headache, which subsided after the cessation of medication; all other patients completed their treatment without severe adverse events. Two patients who had a relapse of HCV were infected with a genotype 3 strain. We observed hyperbilirubinemia in a patient with genotype 3, who was under antiretroviral therapy including atazanavir. He completed the treatment and achieved SVR. Conclusion Direct‐acting antiviral treatment for patients coinfected with HCV/HIV is as effective as in patients infected only with HCV. It was generally well tolerated, except in one patient who discontinued the treatment due to severe headache.